Self-testing Market Size, Share & Trends Analysis Report By Product (Kits, Devices, Strips), By Application, By Sample Type, By Distribution Channel, By Usage, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global self-testing market size was valued at USD 9.98 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.0% from 2023 to 2030. Self-test kits are used for the rapid diagnosis of a wide variety of illnesses. The growth of the market for self-testing is prominently driven by the increasing emphasis on personalized healthcare, technological advancements in rapid diagnostics, and rising demand for convenient and rapid diagnostics kits. Furthermore, the increasing number of product launches is also expected to have a positive impact on the self-testing space.

The COVID-19 pandemic has accelerated the need for self-testing kits with an aim to increase the rate of diagnosis. To reduce the risk of serious diseases, hospitalizations, or death, many organizations have undertaken various efforts. For instance, the Administration for Strategic Preparedness and Response (ASPR) and NIH collaborated to launch the Home Test to Treat program in January 2023. This program is a virtual community health intervention that will provide free COVID-19 health services, such as telehealth consultations, home treatments, and at-home rapid tests in a few selected communities. Such factors further boost the market for self-testing services.

Increasing funding and investments by various organizations as well as market players for the development of novel and robust diagnostics has created lucrative opportunities for the self-testing industry. For instance, in January 2022, the Florida Atlantic University (FAU) approved funding of USD 1.3 million to NIH for the development of quick and automated HIV self-kits. Furthermore, in April 2023, the India-based start-up Cervicheck received approval from the Central Drugs Standard Control Organization (CDSCO) for the commercialization of its kit in India. The kit is used for the diagnosis of Human Papillomavirus (HPV).

The market for self-testing is anticipated to show strong growth, as several initiatives are being taken by major key players, along with numerous ongoing technological advancements. For instance, in November 2022, F. Hoffmann-La Roche introduced the ‘Pilot COVID-19 At-Home Test’, a new name and brand for its COVID-19 At-Home Test, as part of the efforts of the U.S. government to expand access to at-home testing.

Sample Type Insights

The blood sample segment dominated the overall market with the largest revenue share of 35.04% in 2022. The dominance of the segment can be attributed to the increasing use of blood samples for diagnostics due to their non-invasiveness, ability to provide comprehensive insights into various health conditions, as well as advancements in diagnostic technologies. Moreover, increasing product launches with advanced mechanisms are also projected to offer favorable opportunities for segment growth. For instance, in May 2022, Laboratory Corporation of America Holdings announced the launch of its very first at-home blood sample collection device for diabetes diagnostics.

The urine sample segment is expected to witness the fastest growth rate over the forecast period, owing to the increasing use of urinalysis for various disease diagnostics. Besides, the rising capabilities of kits & devices to offer a range of diagnostics insights are also projected to accelerate urine sample segment growth by 2030. In November 2021, Vivoo received USD 6.0 million through series A funding for the development of at-home urine test kits. The kits are integrated with an app and provide hassle-free real-time insights.

Product Insights

The kits product segment dominated the self-testing market with a revenue share of 47.86% in 2022. The segment is also projected to register the fastest CAGR over the forecast period. The growth is attributed to the rising focus of key players on investing in the research & development of new products. For instance, in May 2021, Zoe, a personalized nutrition startup, raised USD 20 million for its at-home testing kits. Moreover, in February 2023, Abingdon Health plc entered into a distribution agreement with Salignostics to extend sales of the latter’s saliva-based pregnancy test kits in Ireland.

The testing strips segment held a considerable market share in 2022, owing to the high usage of strips and their affordability. The increasing geriatric population, growing cases of chronic diseases, and technological advancements in the medical sector are projected to boost the revenue share of the segment.

Application Insights

The allergy test application segment held the largest revenue share of 17.49% in 2022 in the market. The increasing incidence of allergic conditions is one of the key factors contributing to market growth over the forecast period. As per data published by the Asthma and Allergy Foundation of America, in 2021, an estimated 81 million people were detected with hay fever in the U.S. Increasing number of product launches further boosts the market growth. In June 2022, Everlywell launched affordable home tests for food allergy and celiac disease along with virtual follow-up care.

The cancer tests segment is projected to showcase the fastest CAGR over the forecast period. The rising number of cancer cases is a key reason for segment growth. The increasing focus of companies to launch new products further boosts market growth. For instance, in August 2022, Viome Life Sciences launched a self-testing throat cancer test for consumers. The saliva-based tests have shown 95% specificity and 90% sensitivity.

Distribution Channel Insights

On the basis of distribution channel, the offline segment dominated the market for self-testing with a revenue share of 62.97% in 2022. Significant investments by companies in building their own distribution networks are projected to accelerate segment growth. In addition, the increasing number of distribution agreements within companies is also estimated to have a positive impact on segment growth by 2030.

Online channels are projected to expand at the fastest CAGR over the forecast period, as online retailers offer a greater accessibility of self-testing products, allowing easier access to consumers regardless of their location. Online channels offer wider options regarding self-testing products than offline channels and also provide access to niche products, driving their appeal.

Usage Insights

The disposable segment held the largest revenue share of 82.66% of the market in 2022. The segment is further projected to expand at the fastest CAGR over the forecast period. Self-testing is providing new opportunities to detect, diagnose, and address patients and their treatment process. Disposable kits offer exceptional usability due to their convenient and user-friendly nature. They eliminate the need for complex preparation or cleaning, ensuring a hygienic and hassle-free experience. Such advantages of disposable kits along with improved safety are likely to accelerate segment growth during the forecast period.

Reusable kits are expected to hold a considerable market share during the forecast period. Manufacturers are producing testing kits for wellness and preventative measures, including chronic disease treatment and acute infection diagnoses to detect the possible dangers of ailments. Increased cost benefits are likely to offer favorable opportunities for segment growth by 2030.

Regional Insights

North America dominated the overall market in 2022 with a revenue share of 32.40%. The growth of the North American market for self-testing is attributed to rising cases of chronic conditions that require quick diagnosis, technological advancements in the healthcare sector, and the availability of key players. These factors are projected to boost the revenue growth in the region. The increasing number of FDA approvals for new products also boosts the market growth. For instance, in May 2022, empowerDX announced the launch of an at-home celiac disease genetic risk test. The kit performs molecular testing and provides accurate results. 

The Asia Pacific region is projected to expand at the fastest CAGR over the forecast period. The rising number of activities related to research & development of novel therapeutics for infections, the improving healthcare sector, and government initiatives to reduce disease burden are the key factors driving regional market growth. Other factors, such as increasing healthcare reforms, expanding healthcare infrastructure, growing population, rising incidence of chronic diseases, and the growing number of local companies entering the market are also estimated to drive the Asia Pacific market for self-testing during the forecast period.

Key Companies & Market Share Insights

The global market for self-testing is projected to show lucrative growth, as major players are focusing on various strategic initiatives such as launching new products, mergers & acquisitions, and expansion in other regions. For instance, in March 2022, Brain Chemistry Labs announced its plan to develop an easy-to-use rapid self-testing kit in collaboration with Arlington Scientific. The kit will be used for the detection of β-N-methylamino-L-alanine (BMAA) in the body. Some of the prominent companies in the global self-testing market include:

• Johnson & Johnson Services, Inc.

• Geratherm Medical AG

• B. Braun Holding GmbH

• Piramal Enterprises

• Cardinal Health

• OraSure Technologies, Inc.

• bioLytical Laboratories Inc.

• PRIMA Lab SA.

• BD

• F. Hoffmann-La Roche Ltd.

• Bionime Corporation

Self-testing Market Report Scope

Global Self-testing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research, Inc. has segmented the global self-testing market report on the basis of product, sample type, application, distribution channel, usage, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Kits

  • Devices

  • Strips

• Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood

  • Urine

  • Stool

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood Pressure Test

  • Diabetes and Glucose Tests

  • Cholesterol and Triglycerides Tests

  • Pregnancy Test

  • STD /STI Test

  • Urinary Tract Infection Test

  • Cancer Test

  • Celiac disease Test

  • Thyroid Test

  • Transaminase Test

  • Anemia Test

  • Allergy Test

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Online

  • Offline

• Usage Outlook (Revenue, USD Million, 2018 - 2030)

  • Disposable

  • Reusable

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Spain

    • Italy

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait